Safety Profile of PCC1

Comparative Safety of Procyanidin C1 versus Other Senolytics

Based on the currently available literature, Procyanidin C1 (PCC1) demonstrates a clearly superior safety profile compared with mainstream senolytic candidates (Navitoclax/ABT-263, the Dasatinib + Quercetin combination, Fisetin and Piperlongumine), manifesting that:

  • a) it shows the lowest hematologic toxicity signals and enjoys a relatively wide therapeutic window (in vitro and in vivo: 20-200μM)
  • b) it does not carry obvious burden of cardiovascular, neurologic and gastrointestinal adverse events
  • c) its probability of triggering the potential "over-clearance → weakened immune surveillance → preneoplastic progression" cascade is substantially lower, while it simultaneously displays microenvironmental modulation and antiproliferative/immune-supportive "buffering" properties

Hematologic Safety and Overall Tolerability

Navitoclax (ABT-263)

Navitoclax (ABT-263) is notorious for dose-limiting thrombocytopenia—an unavoidable mechanism-based toxicity arising from BCL-xL inhibition. Gandhi et al. found in phase I trials involving SCLC and other solid tumor patients that all participants experienced some degree of thrombocytopenia. The underlying cause of thrombocytopenia is ABT-263's inhibition of the BCL-xL protein, which is a critical survival factor for maintaining the viability of circulating platelets.

Dasatinib

Dasatinib is accompanied by mild-to-moderate neutrophil and platelet declines. For example, several clinical trials reported grade 3–4 thrombocytopenia in patients. With prolonged use, it confers risks of pleural/pericardial effusion and pulmonary arterial hypertension. In a large pooled analysis (n=2,712), the incidence of pleural effusion caused by Dasatinib reached 33–35%.

Quercetin & Fisetin

Clinical trials show that quercetin is safe at doses as high as 5000 mg/day. However, excessive doses may lead to gastrointestinal discomfort. Fisetin, at clinically tolerable low-dose ranges (e.g., 100mg daily for a few weeks), usually induce local and limited changes in inflammatory mediators (e.g., IL-8) and lack consistent broad-spectrum SASP modulation. In some clinical studies, the "hit-and-run" dosing regimen (>1000 mg/day) appears to replicate the broad-spectrum reduction of SASP observed in aged mice. In addition, at higher doses it may be curtailed by gastrointestinal intolerance.

Piperlongumine (PL)

Piperlongumine (PL) produces few hematologic suppression signals at efficacious exposure, yet its pro-oxidative mechanism entails gastrointestinal irritation and potential hepatocellular stress. In toxicity studies involving 28 cell lines, PL demonstrated an IC50 of 21.91 μM for normal peripheral blood mononuclear cells (PBMCs) compared to 1–10 μM for various cancer cell lines, indicating clear selectivity but a relatively narrow therapeutic window.

PCC1 Advantage

By contrast, within all currently attainable efficacious dose ranges, PCC1 has shown no evident bone marrow suppression or acute platelet drop; hematologic fluctuations are minimal, illustrating a wider therapeutic index and a markedly lower monitoring burden. A recent human clinical study has for the first time confirmed that a daily dose of 2.5–5 mg of PCC1 can significantly improve the condition of aging skin, while also validating the efficacy of PCC1 in humans at a relatively lower dose compared to quercetin and fisetin. This is consistent with the results of previous experiments conducted in vitro on cell models and in aged mouse models.

Organ- and System-Level Safety

Dasatinib's cardiovascular and pleural toxicities (arrhythmia, pericardial/pleural effusion, pulmonary arterial hypertension) pose chronic-use warnings. For example, in certain patients, a 24-hour electrocardiogram (ECG) indicated that ventricular arrhythmia returned to baseline levels after a 7-day discontinuation.

Navitoclax, through platelet dysfunction, directly increases the risk of bleeding events, such as skin bleeding, mucosal bleeding, or more severe bleeding complications.

In addition, Dasatinib has sporadically reported sleep disturbance, anxiety or peripheral neuropathy. A case report documented a 54-year-old female who developed limb sensory impairment after two months of Dasatinib treatment, with symptoms improving following a change of medication.

Dasatinib (100mg/day·3days) and Quercetin (1,000–2,000mg/day·2days) When used in combination, due to the 10-20 fold difference in dosage between the two agents and the significant variability in toxicity thresholds among different patients, careful design of dosing regimens is required. Enhanced multi-organ monitoring (particularly platelet counts, liver function, and cardiopulmonary function) should be implemented, along with dose-escalation studies and pharmacokinetic/pharmacodynamic research in clinical trials to determine the optimal safety window.

Fisetin, when escalated to senolytic doses, is frequently limited by gastrointestinal reactions that create an "efficacy–tolerability" trade-off.

In comparison, current data indicate that PCC1 exerts minimal influence on cardiovascular, electrophysiological, neurobehavioral and gastrointestinal parameters, while providing potential anti-inflammatory, neuroprotective and micro-environment-modulating benefits; no concentrated safety signals related to major-organ dysfunction have been observed.

Early Tumor-Biology Considerations

Given the inherent heterogeneity of senescent cells and their complex relationship with cancer cells, the possibility that excessive use of senolytics to eliminate senescent cells may weaken immune surveillance and accelerate early tumor progression cannot be entirely ruled out. For instance, recent reports suggest that D+Q may excessively remove stress-induced senescent cells that still possess inhibitory effects on clonal expansion, while also reducing immune cell infiltration, thereby posing a risk of promoting early tumor development. Such findings caution that broad-spectrum senolytic strategies demand refined population and timing selection.

Theoretically, initiating a similar "promotion chain" requires: (i) an intact preneoplastic OIS stage, (ii) rapid and massive clearance of OIS cells, (iii) a pronounced depletion of immune-chemoattractive SASP, and (iv) a lack of concurrent growth-signal inhibition and effector-T-cell compensation.

PCC1 concurrently offers antiproliferative/signal-pathway modulation (e.g., potential interference with the EGFR/TGF-β axis), immune-microenvironment support, and partial senomorphic (gentle remodeling rather than drastic clearance) features, making it difficult for all of these conditions to align. Consequently, it exhibits a considerably lower pro-tumorigenic potential and a broader overall safety margin in cross-compound comparisons.

In summary, PCC1 delivers a "zero hematologic burden, low organ-system interference, and dual immune & anti-tumor buffering" profile, positioning it as the most comprehensively safe senolytic to date with the least latent pro-tumor risk. Its "low-disruption + multi-dimensional compensation" advantages provide a solid safety foundation for future clinical stratification and combination-strategy exploration.

Safety Profiles and Monitoring Priorities for Multiple Senolytic Candidates

Senolytic Hematologic Safety Organ- and System-level Safety Immune Surveillance / Early Tumor-biology Considerations Monitoring Key Points
Navitoclax Mechanism-based, dose-limiting significant platelet reduction Amplified bleeding risk; indirectly increased cardiovascular events Broad-spectrum clearance or attenuation of OIS "brakes" requires population stratification High-frequency CBC monitoring + bleeding signs
D+Q Mild-to-moderate neutropenia/thrombocytopenia (combination therapy did not show significant alleviation) Pleural/pericardial effusion, pulmonary hypertension, arrhythmias; high-dose quercetin is limited by gastrointestinal irritation and unstable absorption Pre-cancer animal models: rapid clearance of OIS combined with a decrease in CD8+ cells → lowered threshold for immune surveillance weakening cascade Hematological profile + chest imaging/cardiopulmonary function + gastrointestinal tolerance assessment
Fisetin Low hematological risk Gastrointestinal tolerance and solubility/absorption limitations in efficacy enhancement Low-dose SASP exhibits limited inhibitory breadth and requires combination therapy to enhance efficacy Primary focus on gastrointestinal symptoms at high doses
Piperlongumine Bone marrow suppression signals are currently minimal Gastrointestinal mucosal irritation; potential hepatocellular stress; oxidative-inflammatory amplification Excessive oxidation may disrupt immune homeostasis Liver function + gastrointestinal symptoms + oxidative stress biomarkers
PCC1 Extremely low hematological risk. No significant bone marrow suppression or acute platelet drop observed No centralized cardiopulmonary/thoracic/neurotoxicity/hepatotoxicity signals detected; good gastrointestinal tolerance No CD8+ depletion observed; OIS clearance is non-rapid → relatively low risk of "excessive clearance → immune surveillance weakening." Potential low-frequency CBC risk; routine intermittent cardiopulmonary and liver assessments

References

  1. Xu, Q., et al., The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. Nat Metab 3: 1706–1726. 2021.
  2. Liu, X., et al., Single-cell profiling unveils a geroprotective role of Procyanidin C1 in hematopoietic immune system via senolytic and senomorphic effects. npj Aging, 2025. 11(1): p. 31.
  3. Gandhi, L., et al., Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol, 2011. 29(7): p. 909-16.
  4. Josefsson, E.C., et al., Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways. Nat Commun, 2014. 5: p. 3455.
  5. Breccia, M., et al., Systematic review of dasatinib in chronic myeloid leukemia. Onco Targets Ther, 2013. 6: p. 257-65.
  6. Cheng, F., et al., Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies. Front Oncol, 2023. 13: p. 1113462.
  7. Lu, N.T., et al., A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. Phytother Res, 2016. 30(1): p. 160-8.
  8. Han, M.K., et al., Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. BMJ Open Respir Res, 2020. 7(1).
  9. Yousefzadeh, M.J., et al., Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine, 2018. 36: p. 18-28.
  10. Farsad-Naeimi, A., et al., Effect of fisetin supplementation on inflammatory factors and matrix metalloproteinase enzymes in colorectal cancer patients. Food & Function, 2018. 9(4): p. 2025-2031.
  11. Krishnakumar, I.M., et al., Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. J Nutr Sci, 2022. 11: p. e74.
  12. de Lima Moreira, F., et al., Metabolic profile and safety of piperlongumine. Scientific Reports, 2016. 6(1): p. 33646.
  13. Liu, X., et al., Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry, 2018. 26(14): p. 3925-3938.
  14. Study of PCC1 for Skin Rejuvenation. https://clinicaltrials.gov/study/NCT06641869.
  15. Spechbach, H., et al., Reversible ventricular arrythmia induced by dasatinib. Clin Case Rep, 2013. 1(1): p. 20-5.
  16. Inoue, H., et al., Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia. Intern Med, 2020. 59(19): p. 2419-2421.
  17. Kirkland, J.L. and T. Tchkonia, Senolytic drugs: from discovery to translation. J Intern Med, 2020. 288(5): p. 518-536.
  18. Huard, C.A., et al., Effects of Fisetin treatment on cellular senescence of various tissues and organs of old sheep. Antioxidants, 2023. 12(8): p. 1646.
  19. Liu, Y., et al., Senolytic and senomorphic agent procyanidin C1 alleviates structural and functional decline in the aged retina. Proc Natl Acad Sci U S A, 2024. 121(18): p. e2311028121.
  20. Gan, Y., et al., Senolytic procyanidin C1 alleviates renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells. The FASEB Journal, 2025. 39(2): p. e70362.
  21. Wang, J.-H., et al., Procyanidin C1 ameliorates aging-related skin fibrosis through targeting EGFR to inhibit TGFβ/SMAD pathway. Phytomedicine, 2025: p. 156787.
  22. Luo, Y., et al., Senolytic drugs dasatinib and quercetin promote skin papilloma progression by eliminating senescent cells and impairing immune surveillance. Oral Science and Homeostatic Medicine, 2025. 1(1).